SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
Portfolio Pulse from
SpringWorks Therapeutics announced long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO® (nirogacestat) for desmoid tumors, showing further tumor size reduction, increased ORR, additional CRs, sustained symptom improvement, and a consistent safety profile over a median therapy duration of 3 years. These findings will be presented at the CTOS 2024 Annual Meeting.
November 07, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SpringWorks Therapeutics' long-term data from the Phase 3 DeFi trial of OGSIVEO® shows promising results in treating desmoid tumors, with further tumor size reduction and a consistent safety profile over 3 years.
The announcement of positive long-term data from the Phase 3 trial of OGSIVEO® is likely to boost investor confidence in SpringWorks Therapeutics. The data shows significant improvements in tumor reduction and safety, which are critical for the drug's success and potential market approval. This news is highly relevant and important for SpringWorks as it directly impacts their product pipeline and future revenue potential.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90